Investment
Features
FeesSafety
Academy
More
Pluang+

Shake Shack posts strong Q2 with 12.8% profit growth, maintains Buy rating amid growth and margin gains.

Company Fundamentals
21 Sep 2026
Seeking Alpha
View Source
Bullish
Shake Shack posts strong Q2 with 12.8% profit growth, maintains Buy rating amid growth and margin gains.

Shake Shack reported strong Q2 results with a 12.8% year-over-year increase in restaurant-level profit and a 23% margin, achieving $61 million in EBITDA despite cost pressures. The company projects 60–65 new company-operated and 40–45 licensed store openings, revenues of $1.6–$1.7 billion, and adjusted EBITDA between $225–$235 million. Shake Shack maintains a Buy rating as its asset-light model and digital engagement support long-term growth potential, with intrinsic value estimated above the current stock price. The company also shifted to providing annual-only guidance going forward.

Shake Shack's recent performance and outlook provide context for consumer cyclical market activity. For readers following this sector, here is Pluang's market snapshot as of Sep 21, 2026 14:01 WIB: Among 107 priced US Consumer Cyclical stocks, 68 rose and 35 fell. Notable movers include BBWI at USD 17.40 with a +4.00% change, LI at USD 11.68 with a -3.79% change, and HOG at USD 25.93 with a -3.39% change.

More News

Nevada Organic Phosphate extends phosphate mineralization strike to 3 km, advancing 2026 drilling program.

Nevada Organic Phosphate extends phosphate mineralization strike to 3 km, advancing 2026 drilling program.

Nevada Organic Phosphate Inc. has successfully extended the confirmed strike length of its Upper Phosphate Zone to over 3 kilometres through drilling, marking a significant milestone. The company has mobilized Falcon Drilling to continue its 2026 exp...

Market News
Bullish
4 hours ago
Thiogenesis advances TTI-0102 with new clinical trials for rare pediatric diseases, targeting 2027 data.

Thiogenesis advances TTI-0102 with new clinical trials for rare pediatric diseases, targeting 2027 data.

Thiogenesis Therapeutics announced shareholder approvals and updates on its lead drug candidate TTI-0102, aimed at treating serious pediatric diseases like nephropathic cystinosis and Leigh syndrome. The company plans to start clinical studies in lat...

Company Fundamentals
Bullish
4 hours ago
Chainlink (LINK) price rises 6.2% to $12.11, eyeing $13 resistance amid strategic reserve buying.

Chainlink (LINK) price rises 6.2% to $12.11, eyeing $13 resistance amid strategic reserve buying.

Chainlink's (LINK) price increased by about 6.2% to $12.11 after bouncing from support near $11, with technical analysis suggesting a completed five-wave rally that could lead to further gains toward $13 and possibly $15. The Chainlink strategic rese...

Technical Signals
Bullish
4 hours ago
Oil prices drop over 2% as Saudi exports recover and US-Iran talks loom

Oil prices drop over 2% as Saudi exports recover and US-Iran talks loom

Crude oil prices fell more than 2% following signs of recovering Saudi Arabian oil exports and potential renewed US-Iran diplomacy. BP and Shell shares declined in early trading as Brent crude dropped to $101.65 a barrel and WTI to $93.97. The market...

Market News
Bearish
4 hours ago
Cardano integrates with x402 SDK for direct ADA payments via API calls without accounts.

Cardano integrates with x402 SDK for direct ADA payments via API calls without accounts.

Cardano has integrated with the x402 SDK, enabling applications and AI agents to pay for API calls directly in ADA or Cardano-native tokens using standard HTTP requests without needing accounts or API keys. This integration leverages the HTTP 402 "Pa...

Protocol Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App